Market Overview:
The global anti-PD-1 mAb market is expected to grow at a CAGR of 16.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of cancer treatment. Based on type, the global anti-PD-1 mAb market is segmented into 40mg, 100mg, 200mg, and others. The 100mg segment is expected to account for the largest share of the global anti-PD-1 mAb market in 2018. This segment is also projected to grow at a CAGR of 16.8% during the forecast period from 2018 to 2030.
Product Definition:
Anti-PD-1 MAb is a monoclonal antibody that binds to the programmed cell death 1 (PD-1) protein on T cells, blocking its interaction with PD-L1 and PD-L2 proteins. This prevents T cells from being "turned off" by cancer cells and enables them to continue attacking the tumor. Anti-PD-1 MAb is used to treat certain types of cancer, including melanoma, non–small cell lung cancer (NSCLC), renal cell carcinoma, and bladder cancer. It is also being studied in the treatment of other types of cancer.
40mg:
40mg is a human monoclonal antibody that targets PD-1. It works by inhibiting the immune checkpoint protein, which is responsible for signal transduction from cytokines to immune cells. This leads to inhibition of T-cell activation and proliferation during immunization or tumor recognition.
100mg:
100mg is a generic term used for the dosage of drugs. It is a common way to measure the potency of antibodies and proteins. The most commonly used concentration for protein assays is 50 micrograms per liter, while that for antibody assays ranges from 1 to 500 milligrams per liter.
The FDA has approved three drugs under 100mg dosage class: Sandostatin (98 mg), Dovato (98 mg),.
Application Insights:
The other applications segment includes the treatment of cancer such as lung, breast and colorectal cancer. The anti-PD-1 antibody is used in the treatment of these cancers due to its ability to block PD-1 pathway which leads to the inhibition of tumor angiogenesis, immune evasion and stimulation of tumor growth.
In 2017, melanoma patients accounted for around 41% share in North America while it was 17% in Europe. Increasing incidence rates coupled with advanced treatments such as immunotherapy are anticipated to boost product demand from 2018 - 2030 for this particular application segment. In addition, introduction of new products with enhanced efficacy is expected to drive demand over the forecast period. For instance; Keytruda (pembrolizumab), a PDL1 inhibitor developed by Merck KGaA received U.
Regional Analysis:
North America dominated the global anti-PD-1 mAb market in 2017. This is due to the presence of a large number of melanoma and lung cancer patients, which drives demand for immunotherapies in this region. In addition, increasing R&D investments by major companies and rising awareness about immunotherapy drugs are some other factors contributing to North America’s dominance. Asia Pacific is expected to be the fastest growing regional market during the forecast period owing to rapidly improving healthcare infrastructure along with rising incidence rates of cancers & blood diseases such as lymphoma & multiple myeloma that respond well to PD-1 inhibitors. Moreover, increasing approvals and launchings of new products in this region will drive growth further. For instance, Sun Pharma's Zolgensma was approved by FDA for sale in U.S.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the anti-PD-1 mAb market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and around 600,920 people will die from this disease. This number is expected to rise in the coming years due to growing population and aging population.
- Rising prevalence of autoimmune diseases: The rising prevalence of autoimmune diseases is another key growth driver for the anti-PD-1 mAb market. Autoimmune diseases are caused by an abnormal immune response against body tissues and organs, leading to inflammation and tissue damage. There are more than 80 different types of autoimmune diseases affecting millions of people worldwide each year.
- Growing demand for targeted therapies: The growing demand for targeted therapies is another key factor driving growth in the anti-PD-1 mAb market . Targeted therapies are drugs that specifically target molecules or pathways involved in tumor cell proliferation or survival, leading to fewer side effects compared with traditional chemotherapy regimens . This has led to increased interest among pharmaceutical companies in developing novel targeted therapeutics for various cancers .
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-PD-1 MAb Market Research Report
By Type
40mg, 100mg, 200mg, Others
By Application
Melanoma Patients, Lung Cancer Patients, Lymphoma Patients, Other
By Companies
Bristol Myers Squibb, Merck, Junshi Pharma, Innovent Biologics Inc, Hengrui Medicine, Beijing Beigene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Anti-PD-1 MAb Market Report Segments:
The global Anti-PD-1 MAb market is segmented on the basis of:
Types
40mg, 100mg, 200mg, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Melanoma Patients, Lung Cancer Patients, Lymphoma Patients, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb
- Merck
- Junshi Pharma
- Innovent Biologics Inc
- Hengrui Medicine
- Beijing Beigene
Highlights of The Anti-PD-1 MAb Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 40mg
- 100mg
- 200mg
- Others
- By Application:
- Melanoma Patients
- Lung Cancer Patients
- Lymphoma Patients
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-PD-1 MAb Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anti-PD-1 MAb is a type of antibody that fights cancer by blocking the PD-1 receptor. This receptor helps cancer cells to survive and grow. By blocking this receptor, Anti-PD-1 MAb can help stop the spread of cancer cells and help treat existing tumors.
Some of the key players operating in the anti-pd-1 mab market are Bristol Myers Squibb, Merck, Junshi Pharma, Innovent Biologics Inc, Hengrui Medicine, Beijing Beigene.
The anti-pd-1 mab market is expected to grow at a compound annual growth rate of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-PD-1 MAb Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-PD-1 MAb Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-PD-1 MAb Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-PD-1 MAb Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-PD-1 MAb Market Size & Forecast, 2018-2028
4.5.1 Anti-PD-1 MAb Market Size and Y-o-Y Growth
4.5.2 Anti-PD-1 MAb Market Absolute $ Opportunity
Chapter 5 Global Anti-PD-1 MAb Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anti-PD-1 MAb Market Size Forecast by Type
5.2.1 40mg
5.2.2 100mg
5.2.3 200mg
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anti-PD-1 MAb Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anti-PD-1 MAb Market Size Forecast by Applications
6.2.1 Melanoma Patients
6.2.2 Lung Cancer Patients
6.2.3 Lymphoma Patients
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-PD-1 MAb Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-PD-1 MAb Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti-PD-1 MAb Analysis and Forecast
9.1 Introduction
9.2 North America Anti-PD-1 MAb Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti-PD-1 MAb Market Size Forecast by Type
9.6.1 40mg
9.6.2 100mg
9.6.3 200mg
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anti-PD-1 MAb Market Size Forecast by Applications
9.10.1 Melanoma Patients
9.10.2 Lung Cancer Patients
9.10.3 Lymphoma Patients
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anti-PD-1 MAb Analysis and Forecast
10.1 Introduction
10.2 Europe Anti-PD-1 MAb Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti-PD-1 MAb Market Size Forecast by Type
10.6.1 40mg
10.6.2 100mg
10.6.3 200mg
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anti-PD-1 MAb Market Size Forecast by Applications
10.10.1 Melanoma Patients
10.10.2 Lung Cancer Patients
10.10.3 Lymphoma Patients
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anti-PD-1 MAb Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti-PD-1 MAb Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti-PD-1 MAb Market Size Forecast by Type
11.6.1 40mg
11.6.2 100mg
11.6.3 200mg
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anti-PD-1 MAb Market Size Forecast by Applications
11.10.1 Melanoma Patients
11.10.2 Lung Cancer Patients
11.10.3 Lymphoma Patients
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anti-PD-1 MAb Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti-PD-1 MAb Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti-PD-1 MAb Market Size Forecast by Type
12.6.1 40mg
12.6.2 100mg
12.6.3 200mg
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anti-PD-1 MAb Market Size Forecast by Applications
12.10.1 Melanoma Patients
12.10.2 Lung Cancer Patients
12.10.3 Lymphoma Patients
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anti-PD-1 MAb Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti-PD-1 MAb Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti-PD-1 MAb Market Size Forecast by Type
13.6.1 40mg
13.6.2 100mg
13.6.3 200mg
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anti-PD-1 MAb Market Size Forecast by Applications
13.10.1 Melanoma Patients
13.10.2 Lung Cancer Patients
13.10.3 Lymphoma Patients
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-PD-1 MAb Market: Competitive Dashboard
14.2 Global Anti-PD-1 MAb Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol Myers Squibb
14.3.2 Merck
14.3.3 Junshi Pharma
14.3.4 Innovent Biologics Inc
14.3.5 Hengrui Medicine
14.3.6 Beijing Beigene
